Onset of multiple sclerosis associated with anti-TNF therapy
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Therapies aimed at inhibiting tumor necrosis factor (TNF), a proinflammatory cytokine implicated in autoimmune disease are effective, especially for rheumatoid arthritis. We report a patient with new onset MS closely associated with the initiation of anti-TNF therapy for juvenile rheumatoid arthritis. It is possible that the inhibition of TNF triggered MS in this individual.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Induction of apoptosis in mature T cells by tumour necrosis factor
Zheng, L., Fisher, G., Miller, R. E., Peschon, J., Lynch, D. H., & Lenardo, M. J. (1995) · Nature · doi:10.1038/377348a0 · Cited by 1,116
TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study
The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (1999) · Neurology · doi:10.1212/wnl.53.3.457 · Cited by 1,017
Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions.
Selmaj, K., Raine, C. S., Cannella, B., & Brosnan, C. F. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115102 · Cited by 738
van Oosten, B. W., Barkhof, F., Truyen, L., Boringa, J. B., Bertelsmann, F. W., von Blomberg, B. M. E., Woody, J. N., Hartung, H.-P., & Polman, C. H. (1996) · Neurology · doi:10.1212/wnl.47.6.1531 · Cited by 733
Powell, M. B., Mitchell, D., Lederman, J., Buckmeier, J., Zamvil, S. S., Graham, M., Ruddle, N. H., & Steinman, L. (1990) · International Immunology · doi:10.1093/intimm/2.6.539 · Cited by 286
Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes
Raza, A. (2000) · Microscopy Research and Technique · doi:10.1002/1097-0029(20000801)50:3<229::aid-jemt6>3.0.co;2-h · Cited by 101
Selmaj, K. W., & Raine, C. S. (1995) · Neurology · doi:10.1212/wnl.45.6_suppl_6.s44 · Cited by 95
Soluble cytokine receptors: novel immunotherapeutic agents
Fernandez-Botrán, R. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.3.497 · Cited by 56
Inhibitors of tumor necrosis factor-α: Promising agents for the treatment of multiple sclerosis?
Hohlfeld, R. (1996) · Multiple Sclerosis Journal · doi:10.1177/135245859600100619 · Cited by 20
Cited by
Guidelines of care for the management of psoriasis and psoriatic arthritis
Menter, A., Gottlieb, A., Feldman, S. R., Van Voorhees, A. S., Leonardi, C. L., Gordon, K. B., Lebwohl, M., Koo, J. Y. M., Elmets, C. A., Korman, N. J., et al. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.02.039 · Cited by 1,222
Hehlgans, T., & Pfeffer, K. (2005) · Immunology · doi:10.1111/j.1365-2567.2005.02143.x · Cited by 1,048
Greb, J. E., Goldminz, A. M., Elder, J. T., Lebwohl, M. G., Gladman, D. D., Wu, J. J., Mehta, N. N., Finlay, A. Y., & Gottlieb, A. B. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.82 · Cited by 922
Guidelines of care for the management of psoriasis and psoriatic arthritis
Gottlieb, A., Korman, N. J., Gordon, K. B., Feldman, S. R., Lebwohl, M., Koo, J. Y. M., Van Voorhees, A. S., Elmets, C. A., Leonardi, C. L., Beutner, K. R., et al. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.02.040 · Cited by 769
Glial response during cuprizone-induced de- and remyelination in the CNS: lessons learned
Gudi, V., Gingele, S., Skripuletz, T., & Stangel, M. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00073 · Cited by 430
“This is one of the reasons why the cuprizone model is more and more referred to as an animal model for MS pattern III (Torkildsen et al., 2008; Kipp et al., 2009; Liu et al., 2010; Veto et al., 2010; Acs and Komoly, 2012; Kang et al., 2012; Silvestroff et al., 2012).”
Background
Metadata
- Authors
- Sicotte, N. L., & Voskuhl, R. R.
- Venue
- Neurology
- Published
- 2001-11-27
- Volume
- 57
- Issue
- 10
- Pages
- 1885-1888
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W1977233832
- Cited by
- 322
- References
- 9
- FWCI
- 11.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.